Ovum, a Melbourne women’s health startup founded by doctor-turned-entrepreneur Dr Ariella Heffernan-Marks, has raised $4 million in seed funding to expand an AI-powered health platform built around female patients, tripling its valuation to $18 million in a little over a year.
The round was led by Admiralty Capital Group, with participation from Antler, Giant Leap, Aviron Investments, New Zealand’s Foggy Valley Aotearoa, Brisbane Angels and Think & Grow, according to Startup Daily. State-backed investor LaunchVic returned through its Alice Anderson Fund for female founders.
It follows a $1.7 million pre-seed round closed in February 2025, and lands the company at an $18 million post-money valuation, SmartCompany reported.
An AI health journal for the female body
Ovum pitches itself as data infrastructure for women’s health rather than another cycle-tracking app.
The platform captures symptoms, lifestyle factors, biometrics, reproductive-health stages, medications, appointments and medical reports in a single longitudinal record. An AI layer helps users spot patterns and prepare for clinical appointments across more than 20 conditions, including endometriosis, PCOS, migraines, fibromyalgia, ADHD and menopause.
Since launching in August 2025, the app has passed 20,000 downloads and grown about 30 per cent month on month, Startup Daily reported. Users span ages 15 to 84, and Ovum says it has logged tens of thousands of health insights and more than 100,000 AI health conversations.
Notably, 83 per cent of users have opted in to sharing anonymised data for research, a figure the company argues shows appetite for a female-specific health dataset that medicine has historically lacked.
Built from the founder’s own experience
Heffernan-Marks trained and worked as a doctor before founding Ovum in 2022, and has spoken about being dismissed as a patient while managing chronic migraines.
“I’ve sat on both sides of the desk, as a patient and as a doctor, and that’s why this mission matters so much to me,” she told Women’s Agenda.
Her broader argument is about a data gap, not just a design gap. “For too long, women have had to navigate healthcare systems that were not designed around their lived experiences or backed by sufficient female health data,” she said in comments reported by SmartCompany and Startup Daily.
The lead investor framed the deal as a bet on timing and the founder. Amanda Andriano, founding partner at Admiralty Capital Group, said Ovum “combines mission, market timing and technical capability with an exceptional founder uniquely positioned to lead this movement,” per Startup Daily.
Clinical trials and commercial partners
Ovum is trying to move beyond a consumer app into clinical and commercial channels.
The company has launched trials with St George Hospital and the Royal Hospital for Women, which it describes as the first in Australia to assess AI as a preventative health tool designed specifically for women. That claim is Ovum’s own and has not been independently assessed here.
On the commercial side, it lists partnerships spanning insurer Medibank, Fernwood Fitness, the Sweat app, Menopause Friendly Australia and Australian Red Cross Lifeblood, according to SmartCompany.
The new capital will fund team growth and continued development of the underlying women’s health dataset.
Why it matters
The raise is a data point in a broader Australian bet that femtech and health data can be a serious local industry rather than a niche.
The so-called women’s health gap is well documented: women have been under-represented in clinical trials and diagnosed later for conditions such as endometriosis, which affects roughly one in seven Australian women. A tool that structures longitudinal, consented data could feed local research and sharpen diagnosis, if the clinical trials bear it out.
There is also a sovereignty angle. A large, female-specific health dataset built and held in Australia, with hospital partners and state funding through LaunchVic, keeps sensitive data and any downstream AI models onshore rather than routed through offshore platforms. That matters for privacy, consent and who ultimately profits from the insights.
The jobs and skills story is smaller but real. Seed capital of this size typically funds a handful of engineering, clinical and data roles, and Ovum has explicitly earmarked the money for hiring. The involvement of government-backed and returning investors signals confidence that the venture can scale beyond a single app.
The forward look
The harder questions now are clinical and commercial, not technical.
Ovum will need its hospital trials to produce credible evidence that AI-assisted tracking changes outcomes, not just engagement. Regulators are also tightening scrutiny of AI in health, and consumer trust in how intimate health data is used remains fragile after a run of Australian data breaches.
Ovum’s $4 million sits inside a lopsided funding month. In the same June roundup, SmartCompany noted payments giant Airwallex raised US$460 million at a US$16 billion valuation, and consumer startup SavvyWise pulled $1.56 million via equity crowdfunding. Against that, a doctor-led women’s health raise is modest in dollars but outsized in what it signals about where Australian health-data ambitions are heading.
Sources: SmartCompany funding roundup, SmartCompany on Ovum, Startup Daily, Women’s Agenda.
